Hantz Financial Services Inc. Lowers Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Hantz Financial Services Inc. reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 26.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 678 shares of the company’s stock after selling 249 shares during the quarter. Hantz Financial Services Inc.’s holdings in Neurocrine Biosciences were worth $93,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. State Street Corp raised its holdings in Neurocrine Biosciences by 11.7% during the third quarter. State Street Corp now owns 5,148,293 shares of the company’s stock worth $593,186,000 after purchasing an additional 539,936 shares in the last quarter. Los Angeles Capital Management LLC increased its position in Neurocrine Biosciences by 639.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock worth $48,479,000 after purchasing an additional 363,863 shares during the period. Braidwell LP raised its stake in shares of Neurocrine Biosciences by 20.9% during the 3rd quarter. Braidwell LP now owns 917,674 shares of the company’s stock worth $105,734,000 after buying an additional 158,665 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Neurocrine Biosciences by 23.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 533,324 shares of the company’s stock valued at $61,450,000 after buying an additional 102,715 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec boosted its stake in shares of Neurocrine Biosciences by 12.3% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 736,910 shares of the company’s stock valued at $84,907,000 after buying an additional 80,792 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock opened at $151.82 on Friday. The stock has a 50-day simple moving average of $136.97 and a 200-day simple moving average of $131.51. Neurocrine Biosciences, Inc. has a 52-week low of $110.95 and a 52-week high of $157.98. The firm has a market cap of $15.37 billion, a price-to-earnings ratio of 40.70 and a beta of 0.33.

Insider Transactions at Neurocrine Biosciences

In related news, insider Ingrid Delaet sold 272 shares of the business’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $138.10, for a total transaction of $37,563.20. Following the transaction, the insider now directly owns 2,507 shares in the company, valued at $346,216.70. The trade was a 9.79 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Kevin Charles Gorman sold 146,105 shares of the company’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $149.46, for a total transaction of $21,836,853.30. Following the completion of the sale, the director now directly owns 514,596 shares in the company, valued at approximately $76,911,518.16. The trade was a 22.11 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 214,799 shares of company stock worth $31,513,583. 4.30% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms have issued reports on NBIX. BMO Capital Markets cut their price objective on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research report on Thursday, October 17th. Piper Sandler reiterated an “overweight” rating and issued a $160.00 price target on shares of Neurocrine Biosciences in a report on Monday, December 23rd. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday, December 20th. UBS Group upped their target price on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Wedbush reiterated an “outperform” rating and set a $148.00 price target on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $166.10.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.